• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by Psyence Biomedical Ltd.

    12/9/24 1:36:43 PM ET
    $PBM
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $PBM alert in real time by email
    SC 13G/A 1 d931062dsc13ga.htm SC 13G/A SC 13G/A

     

     

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

    SCHEDULE 13G/A

    Under the Securities Exchange Act of 1934

    (Amendment No. 4)*

     

     

    Psyence Biomedical Ltd.

    (Name of Issuer)

    Class A Common Stock, par value $0.0001 per share

    (Title of Class of Securities)

    74449F209

    (CUSIP Number)

    December 6, 2024

    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

      ☐

    Rule 13d-1(b)

     

      ☒

    Rule 13d-1(c)

     

      ☐

    Rule 13d-1(d)

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

    Continued on following pages

    Page 1 of 11 Pages

    Exhibit Index: 10 Page

     

     

     


    CUSIP No. 74449F209       Page 2 of 11 Pages

     

     1   

     NAMES OF REPORTING PERSONS

     

     Harraden Circle Investments, LLC

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     (a) ☐  (b) ☐

     

     3  

     SEC USE ONLY

     

     4  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     Delaware

    NUMBER OF

    SHARES

    BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5    

     SOLE VOTING POWER

     

     0

       6   

     SHARED VOTING POWER

     

     182,323

       7   

     SOLE DISPOSITIVE POWER

     

     0

       8   

     SHARED DISPOSITIVE POWER

     

     182,323

     9   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     182,323

    10  

     CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

     ☐

    11  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

     9.65%

    12  

     TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

     OO, HC, IA


    CUSIP No. 74449F209       Page 3 of 11 Pages

     

     1   

     NAMES OF REPORTING PERSONS

     

     Harraden Circle Investors GP, LP

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     (a) ☐  (b) ☐

     

     3  

     SEC USE ONLY

     

     4  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     Delaware

    NUMBER OF

    SHARES

    BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5    

     SOLE VOTING POWER

     

     0

       6   

     SHARED VOTING POWER

     

     182,323

       7   

     SOLE DISPOSITIVE POWER

     

     0

       8   

     SHARED DISPOSITIVE POWER

     

     182,323

     9   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     182,323

    10  

     CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

     ☐

    11  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

     9.65%

    12  

     TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

     PN, HC


    CUSIP No. 74449F209       Page 4 of 11 Pages

     

     1   

     NAMES OF REPORTING PERSONS

     

     Harraden Circle Investors GP, LLC

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     (a) ☐  (b) ☐

     

     3  

     SEC USE ONLY

     

     4  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     Delaware

    NUMBER OF

    SHARES

    BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5    

     SOLE VOTING POWER

     

     0

       6   

     SHARED VOTING POWER

     

     182,323

       7   

     SOLE DISPOSITIVE POWER

     

     0

       8   

     SHARED DISPOSITIVE POWER

     

     182,323

     9   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     182,323

    10  

     CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

     ☐

    11  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

     9.65%

    12  

     TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

     OO, HC


    CUSIP No. 74449F209       Page 5 of 11 Pages

     

     1   

     NAMES OF REPORTING PERSONS

     

     Harraden Circle Investors, LP

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     (a) ☐  (b) ☐

     

     3  

     SEC USE ONLY

     

     4  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     Delaware

    NUMBER OF

    SHARES

    BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5    

     SOLE VOTING POWER

     

     0

       6   

     SHARED VOTING POWER

     

     91,162

       7   

     SOLE DISPOSITIVE POWER

     

     0

       8   

     SHARED DISPOSITIVE POWER

     

     91,162

     9   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     91,162

    10  

     CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

     ☐

    11  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

     4.82%

    12  

     TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

     PN


    CUSIP No. 74449F209       Page 6 of 11 Pages

     

     1   

     NAMES OF REPORTING PERSONS

     

     Harraden Circle Special Opportunities, LP

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     (a) ☐  (b) ☐

     

     3  

     SEC USE ONLY

     

     4  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     Delaware

    NUMBER OF

    SHARES

    BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5    

     SOLE VOTING POWER

     

     0

       6   

     SHARED VOTING POWER

     

     91,161

       7   

     SOLE DISPOSITIVE POWER

     

     0

       8   

     SHARED DISPOSITIVE POWER

     

     91,161

     9   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     91,161

    10  

     CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

     ☐

    11  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

     4.82%

    12  

     TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

     PN


    CUSIP No. 74449F209       Page 7 of 11 Pages

     

     1   

     NAMES OF REPORTING PERSONS

     

     Frederick V. Fortmiller, Jr.

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     (a) ☐  (b) ☐

     

     3  

     SEC USE ONLY

     

     4  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     United States of America

    NUMBER OF

    SHARES

    BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5    

     SOLE VOTING POWER

     

     0

       6   

     SHARED VOTING POWER

     

     182,323

       7   

     SOLE DISPOSITIVE POWER

     

     0

       8   

     SHARED DISPOSITIVE POWER

     

     182,323

     9   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     182,323

    10  

     CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

     ☐

    11  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

     9.65%

    12  

     TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

     IN, HC


    CUSIP No. 74449F209       Page 8 of 11 Pages

     

    Item 1(a).

    Name of Issuer

    Psyence Biomedical Ltd. (the “issuer”)

     

    Item 1(b).

    Address of Issuer’s Principal Executive Offices

    121 Richmond Street West, Penthouse Suite 1300, Toronto, Ontario M5H 2K1, Canada

     

    Item 2(a).

    Names of Persons Filing

    This Statement is filed on behalf of the following persons (collectively, the “Reporting Persons”):

     

      i)

    Harraden Circle Investors, LP (“Harraden Fund”),

     

      ii)

    Harraden Circle Special Opportunities, LP (“Harraden Special Op Fund”)

     

      iii)

    Harraden Circle Investors GP, LP (“Harraden GP”);

     

      iv)

    Harraden Circle Investors GP, LLC (“Harraden LLC”);

     

      v)

    Harraden Circle Investments, LLC (“Harraden Adviser”); and vi) Frederick V. Fortmiller, Jr. (“Mr. Fortmiller”);

    This Statement relates to Shares (as defined herein) directly beneficially owned by Harraden Fund and Harraden Special Op Fund. Harraden GP is the general partner to Harraden Fund and Harraden Special Op Fund, and Harraden LLC is the general partner of Harraden GP. Harraden Adviser serves as investment manager to Harraden Fund, Harraden Special Op Fund and other high net worth individuals. Mr. Fortmiller is the managing member of each of Harraden LLC and Harraden Adviser. In such capacities, each of Harraden GP, Harraden LLC, Harraden Adviser and Mr. Fortmiller may be deemed to indirectly beneficially own the Shares reported herein directly beneficially owned by Harraden Fund and Harraden Special Op Fund.

     

    Item 2(b).

    Address of Principal Business Office or, if None, Residence

    The address of the principal business office of each Reporting Person is 299 Park Avenue, 21st Floor, New York, NY 10171.

     

    Item 2(c).

    Citizenship

    Each of Harraden Fund, Harraden Special Op Fund and Harraden GP is a Delaware limited partnership. Each of Harraden LLC and Harraden Adviser is a Delaware limited liability company. Mr. Fortmiller is a citizen of the United States of America.

     

    Item 2(d).

    Title of Class of Securities

    Class A Common Stock, par value $0.0001 per share (“Shares”)

     

    Item 2(e).

    CUSIP No. 74449F209

     

    Item 3.

    If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a: This Item 3 is not applicable.


    CUSIP No. 74449F209       Page 9 of 11 Pages

     

    Item 4.

    Ownership

     

    Item 4(a)

    Amount Beneficially Owned

    As of December 6, 2024, each of the Reporting Persons may be deemed the beneficial owner of 182,323 Shares held directly by Harraden Fund, Harraden Special Op Fund and Harraden Adviser.

     

    Item 4(b)

    Percent of Class Fund and Harraden Adviser.

    As of December 6, 2024, each of the Reporting Persons may be deemed the beneficial owner of approximately 9.65% of Shares outstanding. This percentage is based on a total of 1,889,699 Shares outstanding, based on information in the Form 424B3 filed by the Company on November 12, 2024, adjusted for a reverse split effective on November 26, 2024, and the Form 6-K filed by the Company on December 4, 2024.

     

    Item 4(c)

    Number of shares as to which such person has:

     

    (i) Sole power to vote or direct the vote:

         0  

    (ii) Shared power to vote or direct the vote:

         182,323  

    (iii) Sole power to dispose or direct the disposition of:

         0  

    (iv) Shared power to dispose or direct the disposition of:

         182,323  

     

    Item 5.

    Ownership of Five Percent or Less of a Class

    This Item 5 is not applicable.

     

    Item 6.

    Ownership of More than Five Percent on Behalf of Another Person

    This Item 6 is not applicable.

     

    Item 7.

    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person

    See disclosure in Item 2 hereof.

     

    Item 8.

    Identification and Classification of Members of the Group

    This Item 8 is not applicable.

     

    Item 9.

    Notice of Dissolution of Group

    This Item 9 is not applicable.

     

    Item 10.

    Certification

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.


    CUSIP No. 74449F209       Page 10 of 11 Pages

     

    SIGNATURE

    After reasonable inquiry and to the best of its knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

    Date: December 9, 2024

     

    HARRADEN CIRCLE INVESTORS, LP
    HARRADEN CIRCLE SPECIAL OPPORTUNITIES, LP
    By:   HARRADEN CIRCLE INVESTORS GP, LP, its general partner
    By:   HARRADEN CIRCLE INVESTORS GP, LLC, its
      general partner
    By:   /s/ Frederick V. Fortmiller, Jr.
    Title:   Managing Member
    HARRADEN CIRCLE INVESTORS GP, LP
    By:   HARRADEN CIRCLE INVESTORS GP, LLC, its general partner
    By:   /s/ Frederick V. Fortmiller, Jr.
    Title:   Managing Member
    HARRADEN CIRCLE INVESTORS GP, LLC
    By:   /s/ Frederick V. Fortmiller, Jr.
      Managing Member
    HARRADEN CIRCLE INVESTMENTS, LLC
    By:   /s/ Frederick V. Fortmiller, Jr.
      Managing Member
    FREDERICK V. FORTMILLER, JR.
    /s/ Frederick V. Fortmiller, Jr.


    CUSIP No. 74449F209       Page 11 of 11 Pages

     

    Exhibit INDEX

     

    Joint Filing Agreement    11

     

    Get the next $PBM alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $PBM

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $PBM
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Psyence Biomed Further Strengthens Scientific Advisory Board with Appointment of Dr. Dan J. Stein

      Appointment adds significant clinical and scientific expertise in the field of psychedelic-based therapiesNew York, New York--(Newsfile Corp. - March 18, 2025) - Psyence Biomedical Ltd. (NASDAQ:PBM) ("Psyence Biomed" or the "Company") today announced that it has expanded and further strengthened its Scientific Advisory Board (SAB) with the appointment of Dr. Dan J. Stein, a recognized leader in the field of psychopharmacology. He is the Professor and Chair of the Dept of Psychiatry and Mental Health at the University of Cape Town (UCT) and Director of the South African Medical Research Council (MRC) Unit on Risk & Resilience in Mental Disorders. Dr. Stein joins Dr. Albert Garcia-Romeu (Chair

      3/18/25 8:30:00 AM ET
      $PBM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Psyence Biomed Names Albert P. Garcia-Romeu, Ph.D. as Chair of its Newly Created Scientific Advisory Board

      NEW YORK, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (NASDAQ:PBM) ("Psyence Biomed" or the "Company") today announced that it will work closely with Albert P. Garcia-Romeu, Ph.D., to chair and develop its newly created Scientific Advisory Board (SAB). Dr. Garcia-Romeu is a leading psychedelics researcher currently serving as Associate Professor in the Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, as well as Associate Director, Johns Hopkins Center for Psychedelic and Consciousness Research and the Susan Hill Ward Professor in Psychedelics and Consciousness. He is a highly sought after speaker on the therapeutic potential of p

      2/26/25 8:00:00 AM ET
      $PBM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Psyence Biomed Announces Closing of $2.0 Million Private Placement

      NEW YORK, Dec. 27, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (NASDAQ:PBM) ("Psyence Biomed" or the "Company") today announced that it has closed its previously announced private placement for the purchase and sale of an aggregate of 1,000,000 common shares (or pre-funded warrants in lieu thereof), series A common warrants to purchase up to 1,000,000 common shares and short-term series B common warrants to purchase up to 1,000,000 common shares at a purchase price of $2.00 per common share (or per pre-funded warrant in lieu thereof) and accompanying series A common warrant and short-term series B common warrant. The series A common warrants and short-term series B common warrants hav

      12/27/24 4:05:35 PM ET
      $PBM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PBM
    Leadership Updates

    Live Leadership Updates

    See more
    • Psyence Biomed Names Albert P. Garcia-Romeu, Ph.D. as Chair of its Newly Created Scientific Advisory Board

      NEW YORK, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (NASDAQ:PBM) ("Psyence Biomed" or the "Company") today announced that it will work closely with Albert P. Garcia-Romeu, Ph.D., to chair and develop its newly created Scientific Advisory Board (SAB). Dr. Garcia-Romeu is a leading psychedelics researcher currently serving as Associate Professor in the Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, as well as Associate Director, Johns Hopkins Center for Psychedelic and Consciousness Research and the Susan Hill Ward Professor in Psychedelics and Consciousness. He is a highly sought after speaker on the therapeutic potential of p

      2/26/25 8:00:00 AM ET
      $PBM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Psyence Biomedical Announces Results from Annual and Special General Meeting, Share Consolidation and Receipt of Additional Staff Determination from Nasdaq

      NEW YORK, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (NASDAQ:PBM) ("Psyence Biomed" or the "Company") today announced the voting results for each of the matters presented at the Company's annual and special meeting of shareholders held on November 12, 2024 (the "Meeting"). Shareholders were represented in person or by proxy at the meeting holding 21,877,200 common shares, representing approximately 43.5% of Psyence Biomed's 50,334,170 issued and outstanding common shares as of October 10, 2024, the record date for the Meeting. At the Meeting, a total of five resolutions (the "Resolutions" and each a "Resolution") were submitted to and approved by the Company's shareholder

      11/12/24 4:30:00 PM ET
      $PBM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Psyence Biomed Announces the Signing of a Conditional Binding Term Sheet for the Acquisition of Psilocybin-Based Drug Developer Clairvoyant

      Clairvoyant currently executing a fully randomized multi-country Phase IIb clinical trial evaluating a synthetic psilocybin candidate as a potential therapeutic for Alcohol Use Disorder (AUD) Topline data from the ongoing Phase IIb AUD study anticipated in early 2025 NEW YORK, Sept. 06, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (NASDAQ:PBM) ("Psyence Biomed" or the "Company") today announced that the Company has entered into a conditional binding term sheet with privately-held Clairvoyant Therapeutics Inc ("Clairvoyant"), a clinical-stage developer of psilocybin-based therapeutics based in Canada, for the proposed acquisition by Psyence Biomed of 100% of the shareholdings

      9/6/24 7:30:00 AM ET
      $PBM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PBM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Psyence Biomedical Ltd.

      SC 13G - PSYENCE BIOMEDICAL LTD. (0001985062) (Subject)

      12/13/24 9:16:01 AM ET
      $PBM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Psyence Biomedical Ltd.

      SC 13G/A - PSYENCE BIOMEDICAL LTD. (0001985062) (Subject)

      12/9/24 1:36:43 PM ET
      $PBM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Psyence Biomedical Ltd.

      SC 13G/A - PSYENCE BIOMEDICAL LTD. (0001985062) (Subject)

      12/4/24 4:38:27 PM ET
      $PBM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PBM
    SEC Filings

    See more
    • SEC Form 6-K filed by Psyence Biomedical Ltd.

      6-K - PSYENCE BIOMEDICAL LTD. (0001985062) (Filer)

      5/6/25 4:01:32 PM ET
      $PBM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by Psyence Biomedical Ltd.

      6-K - PSYENCE BIOMEDICAL LTD. (0001985062) (Filer)

      4/23/25 4:26:27 PM ET
      $PBM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by Psyence Biomedical Ltd.

      6-K - PSYENCE BIOMEDICAL LTD. (0001985062) (Filer)

      4/11/25 4:00:12 PM ET
      $PBM
      Biotechnology: Pharmaceutical Preparations
      Health Care